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ABSTRACT 
Objective: Helicobacter pylori related gastro-duodenal diseases can be cured by proper treatment therapy. In India, the commercially available 
classic treatment therapy (proton pump inhibitor, amoxicillin, and clarithromycin) for bacterial eradication is available. However, antibiotic 
resistance to the commonly used triple regimen is increasing very rapidly. Considering that treatment including levofloxacin may be an alternative 
to the classic regimen. Therefore, we aimed to verify H. pylori isolates susceptibility to levofloxacin in India. 
Methods: H. pylori were cultured from 56 patients suffering from different gastro-duodenal diseases. Minimum Inhibitory concentration to 
levofloxacin was determined by agar dilution method. 
Results: The clinical diagnosis of 56 patients who were H. pylori culture positive were Gastro Esophageal Reflux Disease (GERD) (n=23), Non-
erosive reflux Disease (NERD) (n=22), Non Ulcer Dyspepsia (NUD) (n=3), Antral Gastritis (n=2), Duodenal ulcer (n=1) and others (n=5). Of the 56 H. 
pylori isolates, the prevalence of levofloxacin resistance was found in 41 H. pylori isolates (73.2%).  
Conclusion: We found that three-fourth of the isolated H. pylori strains of North India showed resistance to levofloxacin which is used for H. pylori 
treatment in other countries. Therefore, the conventional triple therapy comprising amoxicillin and clarithromycin is more appropriate for anti H. 
pylori management in India. 
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Helicobacter pylori (H. pylori) associated gastroduodenal diseases 
can be cured by proper eradication therapy [1]. Based on this 
knowledge, numerous treatments have been tested and the 
currently recommended regimen is a proton pump-inhibitor-based 
triple therapy with two antibiotics between clarithromycin, 
amoxicillin or metronidazole which is also called ‘classic’ regimen 
[2]. In India, the classic triple therapy regimen including 
clarithromycin and amoxicillin has been used as the first choice 
therapy [3, 4]. Treatment regimens that replace the clarithromycin 
with metronidazole compounds are questionable, as evidence in our 
country from the previous reports showed a low eradication efficacy 
due to the high prevalence of metronidazole-resistant bacteria [5-7]. 
Levofloxacin containing triple therapy should be preferred when 
this treatment fail which have shown good eradication rates in other 
countries [1, 8]. Overall, a worldwide increase in H. pylori resistance 
to metronidazole, clarithromycin has been observed, causing a 
decrease in the efficacy of the classic regimen [9, 10]. In India, this 
decrease occurred unevenly due to the size of the country and socio-
economic differences between regions [5-7, 11]. Considering the 
increasing resistance to the commonly used antibiotics, our aim is to 
assess the susceptibility of H. pylori isolates from the patients 
suffering from various gastroduodenal diseases to the levofloxacin 
for choosing the effective therapy for H. pylori eradication. 
In this study, clinical H. pylori strains were isolated from a gastric 
biopsy of a patient suffering from gastro-duodenal diseases seeking 
care at Yashoda Super speciality Hospital, Ghaziabad. Patients who 
had previous gastric surgery and used bismuth, antimicrobial 
agents, H2
Frequency Scale for the Symptoms of GERD (FSSG) questionnaire 
was administered to all the patients by another person. Gastro-
Esophageal reflux disease (GERD) is defined as FSSG questionnaire 
score is >7 with endoscopic evidence of reflux esophagitis, Non 
Erosive Reflux Disease (NERD) has FSSG Score is>7 with no 
endoscopic evidence of reflux esophagitis and Non-ulcer dyspepsia 
(NUD) has FSSG Score is <7 with no evidence of reflux esophagitis 
[12]. One biopsy from the antrum of each patient was used for H. 
pylori culture. The biopsy specimens were cultured on brain heart 
infusion agar (BHIA) medium (Becton Dickinson, Sparks, MD, USA) 
supplemented with 5% Horse Serum; 0.4% Isovitale X (Becton 
Dickinson, Sparks, MD, USA), amphotericin B (8 µg/ml), 
trimethoprim (5 µg/ml) and vancomycin (6 µg/ml) incubated at 37 
°C for 3-6 d under microaerophilic atmospheres (5% O
 receptor antagonists, Proton pump inhibitors within four 
weeks prior to endoscopic examination; or having any of several 
concomitant medical illnesses including cardiac, respiratory, renal 
and liver diseases were excluded from the study. This study was 
approved by the local institutional ethical research review 
committee (AUUP/UEC/2011). All the patients gave their written 
informed consent for participation in the study. 
2; 10% CO2; 
85% N2
The minimum inhibitory concentration (MIC) breakpoint for 
Levofloxacin (Sigma, St Louis, MO, USA), was >1 µg/ml determined 
by agar dilution method as described by European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) guidelines [13]. Two-
fold serial dilution of levofloxacin antibiotic (0.2-2 µg/ml) was used. 
Three microliter of the adjusted inoculum from the BHI broth 
yielding a viable cell count of 1 x 10
) (Double gas incubator, Hera cell 150i). H. pylori were 
identified by colony morphology, gram staining and positive urease, 
oxidase and catalase tests. All the H. pylori stocks were kept in BHI 
broth containing 20% glycerol at-80 °C.  
8 CFU/ml (equivalent to 2 
McFarland turbidity standard unit) [14] was delivered as a spot to 
BHI agar with 5% horse serum plates containing the various 
concentrations of antibiotic (fig. 1). Antibiotic-free control plates 
were inoculated at the beginning and end of each series of plates. All 
plates were incubated under microaerophilic conditions at 37 °C for 
3 d. The MIC was defined as the lowest concentration of the drug 
that inhibited the visible growth of the bacteria.  Differences between 
groups were statistically evaluated by using the chi-square test. 
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Differences were considered significant at the 5% probability level. 
Statistical analysis was performed using SPSS ver. 20 software. 
A total of 56 H. pylori strains isolated from patients between 18-86 y of 
age were included in this study. Out of these, 30 were males 
(45.0±17.9 y) and 26 were females (41.5±15.1 y). Clinical diagnosis in 
these patients revealed GERD (n=23), NERD (n=22), NUD (n=3), antral 
gastritis (n=2), duodenal ulcer (n=1) and others (n=5) (table 1). 
Resistance to levofloxacin was found in 73.2% (41/56; MIC >1 µg/ml) 
of H. pylori isolates. Further testing identified different levels of 
levofloxacin resistance, MIC < 0.2 µg/ml (3/56; 5.4%), 0.5 µg/ml 
(1/56; 1. 8%), 1 µg/ml (10/56; 17.9%), 2 µg/ml (1/56; 1.8%) (fig. 2).  
The distribution of levofloxacin resistance according to gender, age, 
disease outcome was shown in table 1. As for association of 
levofloxacin resistance with gender, age and the clinical outcome no 
significant difference was found (p > 0.05).  
Though, the resistance to levofloxacin was higher in patients with 
NUD (100%) than patients GERD (78.3%) and NERD (77.3%), but 
these differences were not significant (p > 0.05) (table 1).
  
Table 1: Correlation of Levofloxacin resistance of 56 H. pylori isolates according to their clinical information 
Clinical information Levofloxacin-resistant (%) p-value 
Gender Male (n=30) 22 (73.3) 0.99 
 Female (n=26) 19 (73)  
Age 18-40 (n=25) 20 (80) 0.91 
 41-60 (n=21) 14 (66.7)  
 61-86 (n=10) 7 (70)  
Disease diagnosis GERD (n=23) 18 (78.3) 0.90 
 NERD (n=22) 17 (77.3)  
 NUD (n=3) 3 (100)  
 AG (n= 2) 1 (50)  
 DU (n=1) 0 (0)  
 Others (n=5) 2 (40)  
 
  
Fig. 1: Antibiotic Susceptibility test: Brain heart infusion agar (BHIA) media plates containing a specific concentration of antibiotic 
levofloxacin. Three micro liters of the H. pylori inoculum in BHI broth yielding the cell count of 1 × 108
 
 CFU/ml delivered as a spot to the 
BHIA media plate. One to eight numbering indicates different H. pylori isolates. The test was done in duplicates in each media plate. 
Growth of culture shows the levofloxacin-resistant H. pylori isolate and no growth shows levofloxacin-sensitive H. pylori isolate 
 
Fig. 2: Distribution of minimum inhibitory concentration (MIC) 
among the levofloxacin-resistant Helicobacter pylori strains 
isolated from North India 
 
The results are shown from three independent experiments 
Therapeutic failures are ascribed to increasing resistance to 
antibiotic. Antibiotic susceptibility results show controversial 
findings even in the same geographical areas. This may be due to not 
all the therapeutic trials considered the bacterial and host factors 
which finally affects the therapeutic outcome. 
The resistance of H. pylori to commonly used antibiotic 
metronidazole in classic triple therapy has been reported very high 
in India viz. Lucknow (68%), Hyderabad (100%), Chennai (88.2%) 
[5], Gangetic belt of North India (100%) [6], Kolkata (85%) [11] and 
Gujarat (83.2%) [7]. According to the Maastricht III Consensus 
Conference report, metronidazole resistance rate of H. pylori over 
40%, the effectiveness of triple therapy with metronidazole may 
decrease. However, the efficiency of metronidazole containing 
therapy can be enhanced by increasing its dosage, extending its 
duration or adding bismuth salts [15, 16]. 
Another drug of choice in triple therapy is clarithromycin used for 
the treatment for eradication of H. pylori with an efficacy of 90% 
[17]. However, the resistance of H. pylori to clarithromycin varies in 
our country viz. Kolkata (0%) [11], Lucknow (4%) [5], Mumbai 
(91%) [5], Hyderabad (96%) [5] and Gujarat (58.8%) [7]. According 
to the recommended guidelines if the clarithromycin resistance is 
over 15%-20%, therapies with clarithromycin should not be used as 
firsthand treatment. However, therapies with combined 
clarithromycin and bismuth can improve the bactericidal activity of 
clarithromycin. 
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Recently levofloxacin, a broad spectrum antibiotic with a strong 
antimicrobial activity, has been used in eradicating H. pylori in many 
countries. The guidelines suggest that levofloxacin-containing 
therapies as the first line therapy have good efficacy. The resistance 
rate of levofloxacin in other countries ranges between 12%-33% viz. 
France (15%), Germany (22%), Taiwan (12%), South Korea (33%) 
[8], Beijing (29.1%), Xi’an (21.7%) and Shanghai (32.6%) [18]. To 
our knowledge in India prevalence of its resistance has been 
determined in only a limited number of studies including Gujarat 
where the resistance of H. pylori to levofloxacin is 13.8%. In contrast, 
our present study showed very high resistance rate of H. pylori to 
levofloxacin in North India (73.2%), indicating that eradication of H. 
pylori may fail and should not be used in the treatment of H. pylori. 
According to the recommended guidelines, levofloxacin is not the 
good choice for therapeutic regimen if its resistance is over 20% in 
susceptibility test of H. pylori to this antibiotic [19, 20].  
Antimicrobial susceptibility testing is an effective method that tests 
if H. pylori strains are resistant to some antibiotics which improve 
the rate of response to therapy and is cost saving. However this 
could not performed every time at all the places because of the 
culture of H. pylori is time-consuming and costly. 
In this study, we found that three-fourth of the isolated H. pylori 
strains showed resistance to levofloxacin which is used for H. pylori 
treatment in other countries very effectively. Therefore, the 
conventional triple therapy comprising amoxicillin and clarithromycin 
is more appropriate for anti-H. pylori management in India. Treatment 
strategies should be made and changed according to the resistance of 
H. pylori to antibiotics. Further study is needed in more centers. 
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